Affiliation:
1. Department of Innovation in Healthcare and Social Services Emilia‐Romagna Region Bologna Italy
2. Regional Health and Social Care Agency Emilia‐Romagna Region Bologna Italy
3. Department of Diagnostics and Public Health University of Verona Verona Italy
Abstract
ABSTRACTPurposeIn the early stages of the COVID‐19 pandemic, preliminary results that later proved to be incorrect suggested the possible efficacy of anti‐infective drugs such as azithromycin for the treatment of SARS‐CoV‐2 infection. These preliminary data may have influenced the prescription of azithromycin. However, no individual‐level data linking the use of this antibiotic to acute SARS‐CoV‐2 infection are available. The present analysis aims to fill this gap.MethodsA retrospective population‐based cohort design was used including patients diagnosed with SARS‐CoV‐2 infection in the period ranging from February 2020 to February 2022. The data source for antibiotic consumption was the drug database of outpatient prescriptions of Emilia‐Romagna Region (Italy). Antibiotics were classified according to the Anatomical Therapeutic Chemical (ATC) classification system. Consumption rates and percentages of azithromycin DDDs (defined daily doses) during the acute phase of the infection were compared with a previous control period and with the post‐acute phase. Analyses were stratified by four groups according to the prevalent virus variant at time of diagnosis.ResultsComparing the previous control period with the acute phase of infections, the rates of azithromycin consumption (DDD per 1000 individuals per day) increased from 1.17 to 23.11, from 0.80 to 33.03, from 0.81 to 21.01, and from 1.02 to 9.76, in the pre‐Alpha, Alpha, Delta, and Omicron periods, respectively. Similarly, the percentages of individuals receiving azithromycin, and the azithromycin DDDs percentages over total systemic antibiotics DDDs increased in acute phases of infection compared with control periods. The consumption rates and percentages returned to preinfection levels in the post‐acute phase. In the study period, 12.9% of the use of azithromycin in the entire adult population of Emilia‐Romagna was attributable to acute SARS‐CoV‐2 infection.ConclusionsConsidering the low likelihood of bacterial coinfections, the increased azithromycin consumption in the acute phase of SARS‐CoV‐2 infection suggests inappropriate prescribing of this antibiotic.